|
1.
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics. CA Cancer J Clin. 60:277–300. 2010.
|
|
2.
|
Billingsley KG, Burt ME, Jara E, Ginsberg
RJ, Woodruff JM, Leung DH and Brennan MF: Pulmonary metastases from
soft tissue sarcoma: analysis of patterns of diseases and
postmetastasis survival. Ann Surg. 229:602–610. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Gilbert NF, Cannon CP, Lin PP and Lewis
VO: Soft-tissue sarcoma. J Am Acad Orthop Surg. 17:40–47.
2009.PubMed/NCBI
|
|
4.
|
Clark MA, Fisher C, Judson I and Thomas
JM: Soft-tissue sarcomas in adults. N Engl J Med. 353:701–711.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Grimer R, Judson I, Peake D and Seddon B:
Guidelines for the management of soft tissue sarcomas. Sarcoma: May
31, 2010 (Epub ahead of print). doi: 10.1155/2010/506182.
|
|
6.
|
No authors listed. Adjuvant chemotherapy
for localised resectable soft-tissue sarcoma of adults:
meta-analysis of individual data. Sarcoma Meta-analysis
Collaboration. Lancet. 350:1647–1654. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Gortzak E, Azzarelli A, Buesa J, et al: A
randomised phase II study on neo-adjuvant chemotherapy for
‘high-risk’ adult soft-tissue sarcoma. Eur J Cancer. 37:1096–1103.
2001.
|
|
8.
|
Sinkovics JG and Horvath JC: New
developments in the virus therapy of cancer: a histrogical review.
Intervirology. 36:193–214. 1993.PubMed/NCBI
|
|
9.
|
Sinkovics JG and Horvath JC: Natural and
genetically engineered viral agents for oncolysis and gene therapy
of human cancers. Arch Immunol Ther Exp (Warsz). 56(Suppl 1):
3s–59s. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Parato KA, Senger D, Forsyth PA and Bell
JC: Recent progress in the between oncolytic viruses and tumors.
Nat Rev Cancer. 5:965–976. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Coffey MC, Storong JE, Forsyth PA and Lee
PW: Reovirus therapy of tumors with activated Ras pathway. Science.
282:1332–1334. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Sinkovics JG and Horvath JC: Newcastle
disease virus (NDV): brief history of its oncolytic strain. J Clin
Virol. 16:1–15. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Springfeld C, Fielding AK, Peng KW,
Galanis E, Russell SJ and Cattaneo R: Measles virus: improving
natural oncolytic properties by genetic engineering. Viral Therapy
of Human Cancers. Sinkovics JG and Horvath JC: Marcel Dekker Inc;
New York, NY: pp. 459–480. 2005
|
|
14.
|
Stojdl DF, Litchy B, Knowles S, Marius R,
Atkins H, Sonenberg N and Bell JC: Exploiting tumor-specific
defects in interferon pathway with a previously unknown oncolytic
virus. Nat Med. 6:821–825. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Gromeier M, Lachmann S, Rosenfeld MR,
Gutin PH and Wimmer E: Intergenic poliovirus recombinants for
treatment of malignant glioma. Proc Natl Acad Sci USA.
97:6803–6808. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Bodian D: Poliomyelitis. Pathology of the
Nervous System. Minckler J: McGraw-Hill; New York, NY: pp.
2323–2344. 1972
|
|
17.
|
Ren R, Costantini F, Gorgacz EJ, Lee JJ
and Racaniello VR: Transgenic mice expressing a human poliovirus
receptor: a newmodel for poliomyelitis. Cell. 63:353–362. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Koike S, Taya C, Kurata T, Abe S, Ise I,
Yonekawa H and Nomoto A: Transgenic mice susceptible to poliovirus.
Proc Natl Acad Sci USA. 88:951–955. 1991. View Article : Google Scholar
|
|
19.
|
Gromeier M, Alexander L and Wimmer E:
Internal ribosomal entry site substitution eliminates
neurovirulence in intergenic poliovirus recombinants. Proc Natl
Acad Sci USA. 93:2370–2375. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Kauder SE and Racaniello VR: Internal
ribosomal entry site substitution eliminates neurovirulence in
intergenic poliovirus recombinants. Proc Natl Acad Sci USA.
93:2370–2375. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Takai Y, Miyoshi J, Ikeda W and Ogita H:
Nectins and nectin-like molecules: roles in contact inhibition of
cell movement and proliferation. Nat Rev Mol Cell Biol. 9:603–615.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Amano H, Ikeda W, Kawano S, et al:
Interaction and localization of Necl-5 and PDGF receptor beta at
the leading edges of moving NIH3T3 cells: implications for
directional cell movement. Genes Cells. 13:269–284. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Merrill MK, Bernhardt G, Sampson JH,
Wikstrand CJ, Bigner DD and Gromeier M: Poliovirus receptor
CD155-targeted oncolysis of glioma. Neuro Oncol. 6:208–217. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Toyoda H, Hayashi T, Gabbazza EC, et al:
Experimental treatment of human neuroblastoma using live-attenuated
poliovirus. Int J Oncol. 24:49–58. 2004.PubMed/NCBI
|
|
25.
|
Nobis P, Zibirre R, Meyer G, Kuhne J,
Warnecke G and Koch G: Production of a monoclonal antibody against
an epitope on HeLa cells that is the functional poliovirus binding
site. J Gen Virol. 66:2563–2569. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Wakabayashi T, Matsumine A, Nakazora S, et
al: Fibulin-3 negatively regulates chondrocyte differentiation.
Biochem Biophys Res Commun. 391:1116–1121. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Kono T, Imai Y, Yasuda S, et al: The
CD155/poliovirus receptor enhances the proliferation of ras-mutated
cells. Int J Cancer. 122:317–324. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Tomayko MM and Reynald CP: Determination
of subcutaneous tumor size in athymic (nude) mice. Cance Chemother
Pharmacol. 24:148–154. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Mendelsohn CL, Wimmer E and Racaniello VR:
Cellular receptor for poliovirus: molecular cloning, nucleotide
sequence, and expression of a new member of the immunoglobulin
superfamily. Cell. 56:855–865. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Grimer R, Athanasou N, Gerrand C, et al:
UK Guidelines for the Management of Bone Sarcomas. Sarcoma: Dec 29,
2010 (Epub ahead of print). doi: 10.1155/2010/317462.
|
|
31.
|
Solecki D, Wimmer E, Lipp M and Bernhardt
G: Identification and characterization of the cis-acting elements
of the human CD155 gene core promoter. J Biol Chem. 274:1791–1800.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Solecki D, Bernhardt G, Lipp M and Wimmer
E: Identification of nuclear respiratory factor-1 binding site
within the core promoter of polio virus receptor/ CD155 gene. J
Biol Chem. 275:12453–12462. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Marsson D, Jarry A, Baury B, Blanchardie
P, Laboisse C, Lustenberger P and Denis MG: Overexpression of CD155
gene in human colorectal cartinoma. Gut. 49:236–240. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Solecki DJ, Gromeier M, Mueller S,
Bernhardt G and Wimmer E: Expression of the human poliovirus
receptor/ CD155 gene is activated by sonic hedgehog. J Biol Chem.
277:25697–25702. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Li F, Shi W, Capurro M and Filmus J:
Glypican-5 stimulates rhabdomyosarcoma cell proliferation by
activating Hedgehog signaling. J Cell Biol. 192:691–704. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Oue T, Yoneda A, Uehara S, Yamanaka H and
Fukuzawa M: Increased expression of the hedgehog signaling pathway
in pediatric solid malignancies. J Pediatr Surg. 45:387–392. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Minami Y, Ikeda W, Kajita M, Fujito T,
Monden M and Takai Y: Involvement of up-regulated
Necl-5/Tage4/PVR/CD155 in the loss of contact inhibition in
transformed NIH3T3 cells. Biochem Biophys Res Commun. 352:856–860.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Toyoda H, Franco D, Fujita K, Paul AV and
Wimmer E: Replication of poliovirus requires binding of the
poly(rC) binding protein to cloverleaf as well as to the adjacent
C-rich spacer sequence between the cloverleaf and the internal
ribosomal entry site. J Virol. 81:10017–10028. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Gosselin AS, Simonin Y, Guivel-Benhassine
F, et al: Poliovirus-induced apoptosis is reduced in cell
expressing a mutant CD155 selected during presistant poliovirus
infection in neuroblastoma cells. J Virol. 77:790–798. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Whitton JL, Cornell CT and Feuer R: Host
and virus determinants of picornavirus pathogenesis and tropism.
Nat Rev Microbiol. 3:765–776. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Ida-Hosonuma M, Iwasaki T, Yoshikawa T, et
al: The alpha/beta interferon response controls tissue tropism and
pathogenicity of poliovirus. J Virol. 79:4460–4469. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Melnick JL: Enteroviruses: polioviruses,
coxsackieviruses, echoviruses, and newer enteroviruses. Virology.
Fields BN, Knipe DM, Howley PM, et al: Raven Press; New York, NY:
pp. 549–605. 1995
|
|
43.
|
Yang WX, Terasaki T, Shiroki K, et al:
Efficient delivery of circulating poliovirus to the central nervous
system independently of poliovirus receptor. Virology. 229:421–428.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Strebel PM, Ion-Nedelcu N, Baughman AL,
Sutter RM and Cochi SL: Intramuscular injections within 30 days of
immunization with oral poliovirus vaccine - a risk factor for
vaccine-associated paralytic poliomyelitis. N Engl J Med.
332:500–506. 1995. View Article : Google Scholar
|
|
45.
|
Ohka S, Matsuda N, Tohyama K, Oda T,
Morikawa M, Kuge S and Nomoto A: Receptor(CD155)-dependent
endocytosis of poliovirus and retrograde axonal transport of the
endosome. J Virol. 78:7186–7198. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Gromeier M and Wimmer E: Mechanism of
injury-provoked poliomyelitis. J Virol. 72:5056–5060.
1998.PubMed/NCBI
|
|
47.
|
Ochs K, Zeller A, Saleh L, Bassili G, Song
Y, Sonntag A and Niepmann M: Impaired binding of standard
initiation factors mediates poliovirus translation attenuation. J
Virol. 77:115–122. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Toyoda H, Yin J, Mueller S, Wimmer E and
Cello J: Oncolytic treatment and care of neuroblastoma by a novel
attenuated poliovirus in a novel poliovirus-susceptible animal
model. Cancer Res. 67:2857–2864. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Porosnicu M, Mian A and Barber GN: The
oncolytic effect of recombinant vesicular stomatitis virus in
enhanced by expression of the fusion cytosine deaminase/uracil
phosphoribosyltransferase suicide gene. Cancer Res. 63:8366–8376.
2003.
|
|
50.
|
Obuchi M, Fernandez M and Barber GN:
Development of recombinant vesicular stomatitis virus that exploit
defects in host defense to augment specific oncolytic activity. J
Virol. 77:8843–8856. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
51.
|
Pavio N, Couderc T, Girard S, Sgro JY,
Blondel B and Colbère-Garapin F: Expression of mutated poliovirus
receptors in human neuroblastoma cells persistently infected with
poliovirus. Virology. 274:331–342. 2000. View Article : Google Scholar : PubMed/NCBI
|
